Tail End Invests in Continuation Vehicle to Support
MedSpa Partner's Growth

Pittsburgh, PA – February 8, 2024: Tail End Capital (“Tail End”) completed a GP-led secondary investment into a continuation vehicle managed by Persistence Capital Partners (“PCP”), a leading Canadian private equity fund exclusively focused on high-growth opportunities in healthcare services.  The continuation vehicle (“CV”) provides PCP with more time and capital to continue the rapid growth of MedSpa Partners, Inc. (“MSP”), the leading acquirer and operator of top-tier medical aesthetic clinics in North America.

 

PCP raised over $275 million of capital commitments for the CV, which is more than triple the size of the original investment vehicle that was committed in 2019. 

 

“PCP is thrilled to continue supporting the growth of MSP, which has successfully grown into North America’s leading platform for the medspa industry’s leading clinicians,” said John Trang, Partner at PCP and Chairman of MSP.  “We are proud to continue our partnership with one of our best performing investments and look forward to supporting its future success.”

 

Paul Cohn, Partner at Tail End, said: “Tail End is excited to support the continued growth of this market leading medspa platform . The CV extends the value creation path of one of PCP’s top performing companies while providing interim liquidity with attractive returns for a portion of MSP’s 2019 investors.” 

“MSP is a resilient business with proven ways to grow. We’re excited to partner with PCP and MSP management as they continue to expand the platform. The CV’s dry powder will strengthen MSP’s ability to source and fund acquisitions, and invest in innovative initiatives,” said Mike Blume, Partner at Tail End.